Private Wealth Partners LLC Acquires 132,312 Shares of Pfizer Inc. (NYSE:PFE)

Private Wealth Partners LLC boosted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 29.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 579,849 shares of the biopharmaceutical company's stock after purchasing an additional 132,312 shares during the quarter. Pfizer comprises 1.2% of Private Wealth Partners LLC's holdings, making the stock its 25th biggest position. Private Wealth Partners LLC's holdings in Pfizer were worth $15,383,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Wells Trecaso Financial Group LLC grew its stake in shares of Pfizer by 2.5% in the third quarter. Wells Trecaso Financial Group LLC now owns 14,361 shares of the biopharmaceutical company's stock valued at $416,000 after buying an additional 350 shares in the last quarter. Washington Trust Advisors Inc. grew its stake in shares of Pfizer by 0.7% in the third quarter. Washington Trust Advisors Inc. now owns 49,216 shares of the biopharmaceutical company's stock valued at $1,424,000 after buying an additional 360 shares in the last quarter. PSI Advisors LLC grew its stake in shares of Pfizer by 1.4% in the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock valued at $738,000 after buying an additional 385 shares in the last quarter. Western Pacific Wealth Management LP grew its stake in shares of Pfizer by 10.5% in the third quarter. Western Pacific Wealth Management LP now owns 4,073 shares of the biopharmaceutical company's stock valued at $118,000 after buying an additional 386 shares in the last quarter. Finally, Waddell & Associates LLC grew its stake in shares of Pfizer by 1.6% in the third quarter. Waddell & Associates LLC now owns 24,978 shares of the biopharmaceutical company's stock valued at $723,000 after buying an additional 388 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 0.06% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms recently weighed in on PFE. Citigroup decreased their target price on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. Evercore ISI raised shares of Pfizer to a "strong-buy" rating in a research note on Wednesday, October 30th. UBS Group reduced their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. Guggenheim reaffirmed a "buy" rating and set a $33.00 price objective on shares of Pfizer in a research report on Monday, February 10th. Finally, Bank of America reaffirmed a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $31.92.

Pfizer Stock Performance

Shares of Pfizer stock traded up $0.52 during trading on Friday, reaching $26.42. The company's stock had a trading volume of 39,866,963 shares, compared to its average volume of 38,022,176. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The business's 50-day moving average price is $26.28 and its 200-day moving average price is $27.44. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market cap of $149.73 billion, a PE ratio of 18.71, a P/E/G ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the prior year, the business posted $0.10 earnings per share. Pfizer's revenue was up 24.7% compared to the same quarter last year. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.51%. This is an increase from Pfizer's previous quarterly dividend of $0.42. Pfizer's dividend payout ratio is currently 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.